Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results

Michael Garkavij, Katarina Sjögreen Gleisner, Mattias Nickel, Tomas G Ohlsson, Karin Wingårdh, Jan Tennvall

Research output: Contribution to journal › Published meeting abstract › peer-review

Original language	English
Pages (from-to)	524-525
Journal	Cancer Biotherapy and Radiopharmaceuticals
Volume	23
Issue number	4
DOIs	https://doi.org/10.1089/cbr.2008.12Conf-3
Publication status	Published - 2008
Event	Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates - Sheraton Parsippany Hotel, Parsippany, New Jersey, Jersey Duration: 2008 Oct 16 → 2008 Oct 18

Subject classification (UKÄ)

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{f88f0d043aaf4255b2cc78c14e861201,

title = "Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results",

author = "Michael Garkavij and {Sj{\"o}green Gleisner}, Katarina and Mattias Nickel and Ohlsson, {Tomas G} and Karin Wing{\aa}rdh and Jan Tennvall",

year = "2008",

doi = "10.1089/cbr.2008.12Conf-3",

language = "English",

volume = "23",

pages = "524--525",

journal = "Cancer Biotherapy and Radiopharmaceuticals",

issn = "1084-9785",

publisher = "Mary Ann Liebert, Inc.",

number = "4",

note = "Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates ; Conference date: 16-10-2008 Through 18-10-2008",

}

TY - JOUR

T1 - Peptide receptor radionuclide therapy (PRRT) using Lu-177-Dotatate: Early clinical and dosimetric results

AU - Garkavij, Michael

AU - Sjögreen Gleisner, Katarina

AU - Nickel, Mattias

AU - Ohlsson, Tomas G

AU - Wingårdh, Karin

AU - Tennvall, Jan

PY - 2008

Y1 - 2008

U2 - 10.1089/cbr.2008.12Conf-3

DO - 10.1089/cbr.2008.12Conf-3

M3 - Published meeting abstract

SN - 1084-9785

VL - 23

SP - 524

EP - 525

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

IS - 4

T2 - Twelfth Conference on Cancer Therapy with Antibodies and Immunoconjugates

Y2 - 16 October 2008 through 18 October 2008

ER -